MARC-2: An open-label trial to characterize patients with metastatic renal cell carcinoma (mRCC) treated with everolimus after failure of the first VEGFR-TKI therapy.

被引：0
|
作者：
Staehler, Michael D.
Bergmann, Lothar
Gruenwald, Viktor
Huschke, Torsten
Keilholz, Ulrich
Ohlmann, Carsten Henning
Stoeckle, Michael
Weigang-Koehler, Karin
Hauswald, Kirsten
Schaller, Felix
Strassl, Luise
Junker, Kerstin
机构：
[1] Univ Hosp Grosshadern, Munich, Germany
[2] Dept Med, Frankfurt, Germany
[3] Univ Canc Ctr Frankfurt, Frankfurt, Germany
[4] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany
[5] Univ Hosp Jena, Jena, Germany
[6] Charite, Dept Hematol & Med Oncol, CBF, Berlin, Germany
[7] Univ Saarland, Homburg, Germany
[8] Hosp Nurnberg, Nurnberg, Germany
[9] IOMEDICO AG, Freiburg, Germany
[10] Univ Hosp Jena, Dept Urol, Jena, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 05期
关键词：
D O I：
10.1200/jco.2012.30.5_suppl.467
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
467
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Effect of race on survival of metastatic renal cell carcinoma treated with VEGFR-TKI therapy.
    Kuykendal, Adam Rea
    Snavely, Anna C.
    Nielsen, Matthew Edward
    Kim, William Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Open-label phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma (mRCC)
    Agarwala, S. S.
    Wang, J.
    Ye, D.
    Sallo, V.
    Stergiopoulos, S. G.
    Brechenmacher, T.
    Motzer, R. J.
    BJU INTERNATIONAL, 2012, 110 : 15 - 15
  • [3] Updated results of a prospective non-interventional study of everolimus in Germany after failure of the first VEGFR-TKI in metastatic renal cell carcinoma
    Bergmann, L.
    Goebell, P.-J.
    Kube, U.
    Kindler, M.
    Herrmann, E.
    Janssen, J.
    Schmitz, J.
    Weikert, S.
    Kloss, S.
    Steiner, G.
    Jakob, A.
    Staehler, M.
    Steiner, T.
    Overkamp, F.
    Guderian, G.
    Doehn, C.
    ONKOLOGIE, 2012, 35 : 203 - 203
  • [4] Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial
    Staehler, Michael
    Stoeckle, Michael
    Christoph, Daniel C.
    Stenzl, Arnulf
    Potthoff, Karin
    Grimm, Marc-Oliver
    Klein, Dunja
    Harde, Johanna
    Bruning, Fabian
    Goebell, Peter J.
    Augustin, Marinela
    Roos, Frederik
    Benz-Rud, Iris
    Marschner, Norbert
    Gruenwald, Viktor
    INTERNATIONAL JOURNAL OF CANCER, 2021, 148 (07) : 1685 - 1694
  • [5] Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-I subgroup analysis
    Bracarda, S.
    Hutson, T. E.
    Porta, C.
    Figlin, R. A.
    Calvo, E.
    Gruenwald, V.
    Ravaud, A.
    Motzer, R.
    Kim, D.
    Anak, O.
    Panneerselvam, A.
    Escudier, B.
    BRITISH JOURNAL OF CANCER, 2012, 106 (09) : 1475 - 1480
  • [6] Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis
    S Bracarda
    T E Hutson
    C Porta
    R A Figlin
    E Calvo
    V Grünwald
    A Ravaud
    R Motzer
    D Kim
    O Anak
    A Panneerselvam
    B Escudier
    British Journal of Cancer, 2012, 106 : 1475 - 1480
  • [7] EVEROLIMUS IN METASTATIC RENAL CELLS CARCINOMA AFTER PROGRESSION ON CHEMO-IMMUNO AND VEGFR-TKI THERAPY: CASE REPORT
    Lolli, Ivan
    Logroscino, Antonio
    Santorsa, Luigina
    Ercolino, Letizia
    Ronco, Michele
    Gentile, Antonella
    Troccoli, Giuseppe
    ANNALS OF ONCOLOGY, 2009, 20
  • [8] Efficacy of axitinib in patients with metastatic renal cell carcinoma previously treated with both VEGFR-TKI and mTORI
    Mizuno, Ryuichi
    Kosaka, Takeo
    Mikami, Shuji
    Oya, Mototsugu
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Final results of phase IV study MARC-2: everolimus after failure of one prior VEGFR-tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma
    Staehler, M.
    Christoph, D.
    Stoeckle, M.
    Harde, J.
    Stenzl, A.
    Klein, D.
    Benz-Rued, I
    Gruenwald, V
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 204 - 205
  • [10] What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?
    Calvo, Emiliano
    Ravaud, Alain
    Bellmunt, Joaquim
    CANCER TREATMENT REVIEWS, 2013, 39 (04) : 366 - 374
12345